Surrozen, Inc./DE Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Surrozen, Inc./DE (SRZN) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $24.82 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-06
- Surrozen, Inc./DE share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $24.52, a 103.15% increase year-over-year.
- Surrozen, Inc./DE share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $12.07, a 52.98% increase year-over-year.
- Surrozen, Inc./DE share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $7.89, a 786.52% increase year-over-year.
- Surrozen, Inc./DE share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $0.89, a 74.28% decline year-over-year.
- Surrozen, Inc./DE share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $11.48, a 19.09% increase from fiscal 2024.
- Surrozen, Inc./DE share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $9.64, a 25.04% decline from fiscal 2023.
- Surrozen, Inc./DE share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $12.86, a 294.48% increase from fiscal 2022.
- Surrozen, Inc./DE share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $3.26, a 67.82% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $24.82 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $24.52 10-Q · filed 2026-05-06 | |||
| 2025-12-31 | $11.48 10-K · filed 2026-03-23 | |||
| 2025-09-30 | $11.38 10-Q · filed 2025-11-07 | |||
| 2025-06-30 | $11.32 10-Q · filed 2025-08-08 | |||
| 2025-03-31 | $12.07 10-Q · filed 2025-05-09 | |||
| 2024-12-31 | $9.64 10-K · filed 2025-03-31 | |||
| 2024-09-30 | $9.64 10-Q · filed 2024-11-06 | |||
| 2024-06-30 | $9.64 10-Q · filed 2024-08-12 | |||
| 2024-03-31 | $7.89 10-Q · filed 2024-05-08 | |||
| 2023-12-31 | $12.86 10-K · filed 2024-04-10 | |||
| 2023-09-30 | $0.86 10-Q · filed 2023-11-08 | |||
| 2023-06-30 | $0.86 10-Q · filed 2023-08-09 | |||
| 2023-03-31 | $0.89 10-Q · filed 2023-05-10 | |||
| 2022-12-31 | $3.26 10-K · filed 2023-03-31 | |||
| 2022-09-30 | $3.32 10-Q · filed 2022-11-14 | |||
| 2022-06-30 | $3.38 10-Q · filed 2022-08-11 | |||
| 2022-03-31 | $3.46 10-Q · filed 2022-05-11 | |||
| 2021-12-31 | $10.13 10-K · filed 2022-03-28 | |||
| 2021-09-30 | $10.45 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |